Skip to content

URMC Response to CrowdStrike Software Issue

Saturday, July 20: All UR Medicine facilities are open as scheduled and providing safe patient care, with a goal to return all clinical services to full efficiency by early next week.

Patients: click here for more information. Faculty/Staff: click here for information.

Harris A. Gelbard, M.D., Ph.D.

Harris A. Gelbard, M.D., Ph.D.

Neurology , Pediatrics , Child Neurology

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Locations

Epilepsy Center - Brighton

Clinton Crossings, Building C
919 Westfall Road, Suite 220
Rochester, NY 14618

About Me

I am the Director of the Center for Neurotherapeutics Discovery (CND) and a Professor of Neurology, Pediatrics, Neuroscience and Microbiology & Immunology at the University of Rochester Medical Center. The CND grew out of the Center for Neural Development and Disease (CNDD), which was renamed from i...
I am the Director of the Center for Neurotherapeutics Discovery (CND) and a Professor of Neurology, Pediatrics, Neuroscience and Microbiology & Immunology at the University of Rochester Medical Center. The CND grew out of the Center for Neural Development and Disease (CNDD), which was renamed from its original origin as the Center for Aging and Developmental Biology (CADB), started by the first Director, Howard J. Federoff. In 2007, Dr. Federoff left URMC and at his suggestion, I became the interim director of the CADB, until it was renamed the CNDD the following year to reflect our unswerving commitment to understand neurologic disease in the context of development. As we have evolved, it became apparent that our core strengths were reflected in our collective mission to not only understand development of the nervous system, but to create new therapies to fix disease at a molecular level. Thus, we have finally arrived at a collective identity known as the CND.
I came to the URMC as a postdoctoral fellow in 1989, and stayed as a physician-scientist. While I started my career as a developmental neurobiologist and pediatric neurologist interested in how dopamine was affected during early brain injury, I shifted my research focus radically nearly 25 years ago in an attempt to repurpose already FDA-approved medicines for the treatment of neurologic disease associated with HIV-1 infection. Frustrated by the realization that our progress was incremental, I lead an interdisciplinary, international team to develop a new class of small molecule therapeutics that target mixed lineage kinases. Our efforts evolved to the point where we have secured three internationally prosecuted composition of matter and methods of use patents for these compounds, and we are more than halfway through investigational new drug-enabling studies for our development compound, URMC-099. These experiences have placed me at an intersection between preclinical laboratory efforts to understand relationships between immune effector cells in the central nervous system and synaptic repair during neuroinflammation, and the many steps necessary to bring small molecule technologies into existence as potential drugs. Thus, I feel privileged as the Director that the CND represents a unique opportunity for our investigators to ask questions about disease and answer them with new pathways to therapy.

Certified Specialties

Neurology with Special Qualification in Child Neurology - American Board of Psychiatry & Neurology

Faculty Appointments

Professor - Department of Neurology, Child Neurology (SMD)

Professor - Department of Neuroscience (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, McLean Hospital. 1988 - 1990

Fellowship, Neurology, Children's Hospital of Boston. 1988 - 1990

Residency, Neurology, Children's Hospital of Boston. 1985 - 1988

Residency, Pediatrics, Children's Memorial Hospital. 1984 - 1985

Internship, Pediatrics, Children's Memorial Hospital. 1983 - 1984

Education

MD | Northwestern University Feinberg School of Medicine. 1983

Awards

Herman and Gertrude Silver Award on Children, Youth and HIV. 2019

Awardee of the Hilary Koprowski Prize in Neurovirology. 2016

Inaugural Awardee of the Translational Research in NeuroVirology Lectureship. 2015

Child Neurology Young Investigator Award. 1990

Buswell Memorial Fellowship, University of Rochester. 1990

First Prize, Wyeth-Ayerst Award or New Psychiatric Research, VIII World Congress of Psychiatry, Athens, Greece. 1989

Sigma Xi, Thesis Research. 1980

National Merit Scholar. 1972

Research

Our lab's interests have been shaped by trying to understand how HIV-1 can disrupt normal cognitive functions by altering homeostasis between microglia and synaptic networks. Much like experience-driven synaptic plasticity, this has been and continues to be a work in progress influenced by our trai...
Our lab's interests have been shaped by trying to understand how HIV-1 can disrupt normal cognitive functions by altering homeostasis between microglia and synaptic networks. Much like experience-driven synaptic plasticity, this has been and continues to be a work in progress influenced by our trainees' interests, the experimental approaches they have formulated to help us understand how innate immunity can both shape and repair the central nervous system (CNS), and the novel results that they have produced. Our laboratory has no single technique that has influenced our approach to understanding how the virus can disrupt normal synaptic transmission, although we favor methods that allow us to visualize our data, preferably in real time. Because my training as a molecular neuropharmacologist has emphasized understanding how signaling pathways can be disrupted during disease and whether these pathways can be restored to a new homeostatic relationship between the immune system and vulnerable synaptic networks, we have focused on kinase signaling that controls neuroinflammation. Our efforts to both understand how HIV-1 infection in the CNS disrupts this type of kinase signaling and create small molecule inhibitors of the mixed lineage kinases (MLKs) so that we could test this as a therapeutic approach to HIV-1 associated neurocognitive disorders (HAND), led us to the current point of successfully developing a new class of drugs that inhibit MLKs in macrophages/microglia and neurons to restore homeostasis. This has been extraordinarily serendipitous for us, because we have realized that loss of homeostasis between an end organ target cell, whether it is a neuron, cardiomyocyte or hepatocyte can be restored, with disease-modifying outcomes in HAND, MS (using an EAE model employed by Dr. Matt Bellizzi in our lab), post-operative cognitive dysfunction (POCD; in collaboration with Dr. Niccolo Terrando at Duke University), Alzheimer's disease (with Dr. Gendelman at UNMC and Drs. Todd Krauss and Brad Nilsson at UR), non-alcoholic steatohepatitis (NASH; in collaboration with Dr. Samar Ibrahim at Mayo Clinic) and ischemia-reperfusion injuries (MI; in collaboration with Dr. Burns Blaxall at the Cincinnati Children's Hospital). Lastly, and perhaps most importantly to our lab's core mission, in work we have done with Dr. Howard Gendelman (UNMC) and Drs. Maggirwar and Dewhurst here at URMC, we have discovered that the combination of nanoformulated antiretroviral therapy (nanoART, developed by Dr. Gendelman) for HIV-1 and our lead compound for inhibition of MLKs, URMC-099, can reverse HIV-1 blockade of autophagy in persistently infected macrophages, allowing nanoART to effectively eliminate HIV-1 without inflammation and bystander cellular damage. This has led to additional approaches to new therapies both for HAND and eradication of persistent HIV-1 infection.
For trainees at the pre- and postdoctoral level, we are currently investigating the role of the transcription factor, Mafb, using a combination of optogenetic and CRISPR/Cas9 techniques, in regulating a neuroinflammatory response during HIV-1 infection of the CNS; the role of soluble intercellular adhesion molecule type 5 (sICAM-5) as a biomarker for synaptodendritic damage during HAND; dysregulation of complement signaling during HAND and MS; and therapeutic strategies to repair hippocampal and cortical synaptic injury during MS that remain resistant to current immunomodulatory therapies. Additional projects related to our collaborations with other investigators described above are also ongoing.

Patents

MLK Inhibitors and Methods of Use

Issue date: October 24, 2017

Patent #: 2,744,498

Country: Canada

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: November 04, 2015

Patent #: 2379561

Country: Europe

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: May 13, 2016

Patent #: 5930278

Country: Japan

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

Substituted Pyrrolo [2,3-B] Pyridines as MLK Inhibitors

Issue date: November 04, 2014

Patent #: 8,877,772

Country: United States

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: February 11, 2015

Patent #: ZL200980152665.1

Country: China, People's Republic of

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: July 23, 2015

Patent #: 2009324894

Country: Australia

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use

Issue date: March 30, 2017

Patent #: 2011258465

Country: Australia

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Satheesh Babu Ravula, Torsten Wiemann

Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use

Issue date: August 28, 2018

Patent #: 2,800,176

Country: Canada

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Satheesh Babu Ravula, Torsten Wiemann

Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use

Issue date: February 03, 2015

Patent #: 603644

Country: New Zealand

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Satheesh Babu Ravula, Torsten Wiemann

Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use

Issue date: September 30, 2014

Patent #: 8,846,909

Country: United States

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Satheesh Babu Ravula, Torsten Wiemann

Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use

Issue date: February 10, 2016

Patent #: ZL201180036376.2

Country: China, People's Republic of

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Satheesh Babu Ravula, Torsten Wiemann

Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use

Issue date: February 10, 2017

Patent #: 6086326

Country: Japan

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Satheesh Babu Ravula, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: June 30, 2015

Patent #: 614904

Country: New Zealand

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

Mixed Lineage Kinase Inhibitors and Method of Treatments

Issue date: June 21, 2016

Patent #: 9,370,515

Country: United States

Inventors: Harris A Gelbard, Val S Goodfellow, Thong X Nguyen, Satheesh Babu Ravula

Substituted Pyrrolo [2,3-B] Pyridines as MLK Inhibitors

Issue date: November 10, 2015

Patent #: 9,181,247

Country: United States

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: January 22, 2016

Patent #: 5873544

Country: Japan

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies

Issue date: August 10, 2018

Patent #: ZL201380060736.1

Country: China, People's Republic of

Inventors: Stephen Dewhurst, Harris A Gelbard, Howard E Gendelman

Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies

Issue date: January 09, 2019

Patent #: 2925319

Country: Europe

Inventors: Stephen Dewhurst, Harris A Gelbard, Howard E Gendelman

Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies

Issue date: November 26, 2019

Patent #: 10,485,800

Country: United States

Inventors: Stephen Dewhurst, Harris A Gelbard, Howard E Gendelman

MLK Inhibitors and Methods of Use

Issue date: November 04, 2015

Patent #: FR2379561

Country: France

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: November 04, 2015

Patent #: DE2379561

Country: Germany

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: November 04, 2015

Patent #: IT2379561

Country: Italy

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: November 04, 2015

Patent #: ES2379561

Country: Spain

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

MLK Inhibitors and Methods of Use

Issue date: November 04, 2015

Patent #: GB2379561

Country: United Kingdom

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

Substituted Pyrrolo [2,3-b] Pyridines as MLK Inhibitors

Issue date: November 14, 2017

Patent #: 9,814,704

Country: United States

Inventors: Stephen Dewhurst, Harris A Gelbard, Val S Goodfellow, Colin J Loweth, Torsten Wiemann

Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies

Issue date: January 09, 2019

Patent #: FR2925319

Country: France

Inventors: Stephen Dewhurst, Harris A Gelbard, Howard E Gendelman

Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies

Issue date: January 09, 2019

Patent #: 602013049719.2

Country: Germany

Inventors: Stephen Dewhurst, Harris A Gelbard, Howard E Gendelman

Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies

Issue date: January 09, 2019

Patent #: GB2925319

Country: United Kingdom

Inventors: Stephen Dewhurst, Harris A Gelbard, Howard E Gendelman

Publications

Journal Articles

SARS and synapses.

Gelbard HA, Chiang W

Nature microbiology.. 2024 April 23 Epub 04/23/2024.

Long-term outcomes after new onset seizure in children living with HIV: A cohort study.

Birbeck GL, Mwenechanya M, Ume-Ezeoke I, Mathews M, Bositis CM, Kalungwana L, Bearden D, Elafros M, Gelbard HA, Theodore WH, Koralnik IJ, Okulicz JF, Johnson BA, Musonda N, Siddiqi OK, Potchen MJ, Sikazwe I

Epilepsia open.. 2024 February 17 Epub 02/17/2024.

Early Initiation of Antiretroviral Therapy is Protective Against Seizures in Children with HIV in Zambia: A Prospective Case-Control Study.

Bearden DR, Mwanza-Kabaghe S, Bositis CM, Dallah I, Johnson BA, Siddiqi OK, Elafros MA, Gelbard HA, Okulicz JF, Kalungwana L, Musonda N, Theodore WH, Mwenechanya M, Mathews M, Sikazwe IT, Birbeck GL

Journal of acquired immune deficiency syndromes : JAIDS.. 2023 November 28 Epub 11/28/2023.

Neutrophilia with damage to the blood-brain barrier and neurovascular unit following acute lung injury.

Li H, Le L, Marrero M, David-Bercholz J, Caceres AI, Lim C, Chiang W, Majewska A, Terrando N, Gelbard H

Research square.. 2023 October 23 Epub 10/23/2023.

Neutrophilia with damage to the blood-brain barrier and neurovascular unit following acute lung injury.

Li H, Le L, Marrero M, David-Bercholz J, Caceres AI, Lim C, Chiang W, Majewska AK, Terrando N, Gelbard HA

bioRxiv : the preprint server for biology.. 2023 October 17 Epub 10/17/2023.

Hybrid Amyloid Quantum Dot Nanoassemblies to Probe Neuroinflammatory Damage.

Chiang W, Urban JM, Yanchik-Slade F, Stout A, Nilsson BL, Gelbard HA, Krauss TD

bioRxiv : the preprint server for biology.. 2023 September 1 Epub 09/01/2023.

Quantum Dot Biomimetic for SARS-CoV-2 to Interrogate Blood-Brain Barrier Damage Relevant to NeuroCOVID Brain Inflammation.

Chiang W, Stout A, Yanchik-Slade F, Li H, Terrando N, Nilsson BL, Gelbard HA, Krauss TD

ACS applied nano materials.. 2023 August 256 (16):15094-15107. Epub 08/07/2023.

URMC-099 prophylaxis prevents hippocampal vascular vulnerability and synaptic damage in an orthopedic model of delirium superimposed on dementia.

Miller-Rhodes P, Li H, Velagapudi R, Chiang W, Terrando N, Gelbard HA

FASEB journal : official publication of the Federation of American Societies for Experimental Biology.. 2022 June 36 (6):e22343. Epub 1900 01 01.

Matters of size: Roles of hyaluronan in CNS aging and disease.

Zakusilo FT, Gelbard HA, Seluanov A, Kerry O'Banion M, Gorbunova V

Ageing research reviews.. 2021 December 72 :101485. Epub 10/09/2021.

Quantum Dots for Improved Single-Molecule Localization Microscopy.

Urban JM, Chiang W, Hammond JW, Cogan NMB, Litzburg A, Burke R, Stern HA, Gelbard HA, Nilsson BL, Krauss TD

The journal of physical chemistry. B. 2021 March 18125 (10):2566-2576. Epub 03/08/2021.

The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases.

Qiu WQ, Luo S, Ma SA, Saminathan P, Li H, Gunnersen JM, Gelbard HA, Hammond JW

Frontiers in immunology.. 2021 12 :607641. Epub 04/15/2021.

The Cell Culture Environment Regulates the Transcription Factor MafB in BV-2 Microglia.

Miller-Rhodes P, Gelbard HA

Matters.. 2021 2021 Epub 01/29/2021.

This Is Your Brain on (Low) Glucose.

Miller-Rhodes P, Gelbard HA, Terrando N

Trends in neurosciences.. 2020 December 43 (12):933-935. Epub 09/17/2020.

Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia.

Navis A, Dallah I, Mabeta C, Musukuma K, Siddiqi OK, Bositis CM, Koralnik IJ, Gelbard HA, Theodore WH, Okulicz JF, Johnson BA, Sikazwe I, Bearden DR, Birbeck GL

Epilepsia.. 2020 December 61 (12):2705-2711. Epub 10/21/2020.

Survival and Motor Phenotypes in FVB C9-500 ALS/FTD BAC Transgenic Mice Reproduced by Multiple Labs.

Nguyen L, Laboissonniere LA, Guo S, Pilotto F, Scheidegger O, Oestmann A, Hammond JW, Li H, Hyysalo A, Peltola R, Pattamatta A, Zu T, Voutilainen MH, Gelbard HA, Saxena S, Ranum LPW

Neuron.. 2020 November 25108 (4):784-796.e3. Epub 10/05/2020.

Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis.

Hammond JW, Bellizzi MJ, Ware C, Qiu WQ, Saminathan P, Li H, Luo S, Ma SA, Li Y, Gelbard HA

Brain, behavior, and immunity.. 2020 July 87 :739-750. Epub 03/06/2020.

Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia.

Wang P, Velagapudi R, Kong C, Rodriguiz RM, Wetsel WC, Yang T, Berger M, Gelbard HA, Colton CA, Terrando N

Alzheimer's & dementia : the journal of the Alzheimer's Association.. 2020 May 16 (5):734-749. Epub 04/14/2020.

The darker side of varicella zoster infection: Arterial ischemic stroke.

Pavlakis S, Gelbard HA

Neurology.. 2020 February 494 (5):193-194. Epub 12/31/2019.

The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders.

Miller-Rhodes P, Kong C, Baht GS, Saminathan P, Rodriguiz RM, Wetsel WC, Gelbard HA, Terrando N

Journal of neuroinflammation.. 2019 October 2816 (1):193. Epub 10/28/2019.

Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages.

Saminathan P, Kevadiya BD, Marker DF, Gendelman HE, Gorantla S, Gelbard HA

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2019 March 14 (1):44-51. Epub 01/07/2019.

HIV Tat causes synapse loss in a mouse model of HIV-associated neurocognitive disorder that is independent of the classical complement cascade component C1q.

Hammond JW, Qiu WQ, Marker DF, Chamberlain JM, Greaves-Tunnell W, Bellizzi MJ, Lu SM, Gelbard HA

Glia.. 2018 December 66 (12):2563-2574. Epub 10/16/2018.

URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease.

Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Zhang G, Lee Mosley R, Gelbard HA, Gendelman HE

Journal of neuroinflammation.. 2018 May 515 (1):137. Epub 05/05/2018.

The Mixed-Lineage Kinase Inhibitor URMC-099 Protects Hippocampal Synapses in Experimental Autoimmune Encephalomyelitis.

Bellizzi MJ, Hammond JW, Li H, Gantz Marker, Marker DF, Freeman RS, Gelbard HA

eNeuro.. 2018 5 (6)Epub 12/03/2018.

Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis.

Tomita K, Kohli R, MacLaurin BL, Hirsova P, Guo Q, Sanchez LHG, Gelbard HA, Blaxall BC, Ibrahim SH

JCI insight.. 2017 August 32 (15)Epub 08/03/2017.

Neuroimmune Pharmacology, 2nd Edition - A Perspective.

Gelbard HA

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2017 June 12 (2):211-212. Epub 03/23/2017.

The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-? degradation.

Dong W, Embury CM, Lu Y, Whitmire SM, Dyavarshetty B, Gelbard HA, Gendelman HE, Kiyota T

Journal of neuroinflammation.. 2016 July 1113 (1):184. Epub 07/11/2016.

Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis.

Bellizzi MJ, Geathers JS, Allan KC, Gelbard HA

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2016 January 2736 (4):1336-46. Epub 1900 01 01.

The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.

Zhang G, Guo D, Dash PK, Araínga M, Wiederin JL, Haverland NA, Knibbe-Hollinger J, Martinez-Skinner A, Ciborowski P, Goodfellow VS, Wysocki TA, Wysocki BJ, Poluektova LY, Liu XM, McMillan JM, Gorantla S, Gelbard HA, Gendelman HE

Nanomedicine : nanotechnology, biology, and medicine.. 2016 January 12 (1):109-22. Epub 10/22/2015.

Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders.

Puccini JM, Marker DF, Fitzgerald T, Barbieri J, Kim CS, Miller-Rhodes P, Lu SM, Dewhurst S, Gelbard HA

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2015 April 135 (13):5271-83. Epub 1900 01 01.

Allotransplanted DRG neurons or Schwann cells affect functional recovery in a rodent model of sciatic nerve injury.

Dayawansa S, Wang EW, Liu W, Markman JD, Gelbard HA, Huang JH

Neurological research.. 2014 November 36 (11):1020-1027. Epub 05/18/2014.

Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.

Gendelman HE, Gelbard HA

Current opinion in HIV and AIDS.. 2014 November 9 (6):585-90. Epub 1900 01 01.

Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.

Guo D, Zhang G, Wysocki TA, Wysocki BJ, Gelbard HA, Liu XM, McMillan JM, Gendelman HE

Journal of virology.. 2014 September 188 (17):9504-13. Epub 06/11/2014.

MLK3 regulates fMLP-stimulated neutrophil motility.

Polesskaya O, Wong C, Lebron L, Chamberlain JM, Gelbard HA, Goodfellow V, Kim M, Daiss JL, Dewhurst S

Molecular immunology.. 2014 April 58 (2):214-22. Epub 01/03/2014.

Biomarkers and neurodevelopment in perinatally HIV-infected or exposed youth: a structural equation model analysis.

Kapetanovic S, Griner R, Zeldow B, Nichols S, Leister E, Gelbard HA, Miller TL, Hazra R, Mendez AJ, Malee K, Kammerer B, Williams PL,

AIDS.. 2014 January 2828 (3):355-64. Epub 1900 01 01.

Ultrastructure of microglia-synapse interactions in the HIV-1 Tat-injected murine central nervous system.

Tremblay MÈ, Marker DF, Puccini JM, Muly EC, Lu SM, Gelbard HA

Communicative & integrative biology. 2013 November 16 (6):e27670. Epub 12/31/2013.

Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen TX, Xu Y, Todd DE, Sheppard DW, Pollack S, Polesskaya O, Marker DF, Dewhurst S, Gelbard HA

Journal of medicinal chemistry.. 2013 October 2456 (20):8032-48. Epub 10/03/2013.

Lipids and cognition make good bedfellows for neuroAIDS.

Gelbard HA, Gendelman HE

Neurology.. 2013 October 2281 (17):1480-1. Epub 09/11/2013.

The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.

Marker DF, Tremblay ME, Puccini JM, Barbieri J, Gantz Marker MA, Loweth CJ, Muly EC, Lu SM, Goodfellow VS, Dewhurst S, Gelbard HA

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2013 June 1233 (24):9998-10010. Epub 1900 01 01.

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, Difrancesco R, Hochreiter JS, Morse GD, Schifitto G

Journal of neurovirology.. 2013 June 19 (3):254-60. Epub 06/05/2013.

LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein.

Marker DF, Puccini JM, Mockus TE, Barbieri J, Lu SM, Gelbard HA

Journal of neuroinflammation.. 2012 November 299 :261. Epub 11/29/2012.

Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

Dash PK, Gendelman HE, Roy U, Balkundi S, Alnouti Y, Mosley RL, Gelbard HA, McMillan J, Gorantla S, Poluektova LY

AIDS.. 2012 November 1326 (17):2135-44. Epub 1900 01 01.

Near-field quantification of complement receptor 1 (CR1/CD35) protein clustering in human erythrocytes.

Lapin ZJ, Höppener C, Gelbard HA, Novotny L

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2012 September 7 (3):539-43. Epub 02/29/2012.

Allotransplanted neurons used to repair peripheral nerve injury do not elicit overt immunogenicity.

Liu W, Ren Y, Bossert A, Wang X, Dayawansa S, Tong J, He X, Smith DH, Gelbard HA, Huang JH

PloS one.. 2012 7 (2):e31675. Epub 02/09/2012.

Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Dash PK, Gorantla S, Gendelman HE, Knibbe J, Casale GP, Makarov E, Epstein AA, Gelbard HA, Boska MD, Poluektova LY

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2011 March 231 (9):3148-57. Epub 1900 01 01.

Mitochondrial membrane potential probes and the proton gradient: a practical usage guide.

Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA

BioTechniques.. 2011 February 50 (2):98-115. Epub 1900 01 01.

Two-photon NADH imaging exposes boundaries of oxygen diffusion in cortical vascular supply regions.

Kasischke KA, Lambert EM, Panepento B, Sun A, Gelbard HA, Burgess RW, Foster TH, Nedergaard M

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.. 2011 January 31 (1):68-81. Epub 09/22/2010.

HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells.

Lu SM, Tremblay MÈ, King IL, Qi J, Reynolds HM, Marker DF, Varrone JJ, Majewska AK, Dewhurst S, Gelbard HA

PloS one.. 2011 6 (9):e23915. Epub 09/02/2011.

Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.

Polesskaya O, Cunningham LL, Francis SP, Luebke AE, Zhu X, Collins D, Vasilyeva ON, Sahler J, Desmet EA, Gelbard HA, Maggirwar SB, Walton JP, Frisina RD, Dewhurst S

Hearing research.. 2010 December 1270 (1-2):21-7. Epub 10/27/2010.

Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax.

Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, Stout A, Lu R, Kiebala M, Maggirwar SB, Gelbard HA

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2010 October 2030 (42):14153-64. Epub 1900 01 01.

Rebuilding synaptic architecture in HIV-1 associated neurocognitive disease: a therapeutic strategy based on modulation of mixed lineage kinase.

Gelbard HA, Dewhurst S, Maggirwar SB, Kiebala M, Polesskaya O, Gendelman HE

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.. 2010 October 7 (4):392-8. Epub 1900 01 01.

A thin-skull window technique for chronic two-photon in vivo imaging of murine microglia in models of neuroinflammation.

Marker DF, Tremblay ME, Lu SM, Majewska AK, Gelbard HA

Journal of visualized experiments : JoVE.. 2010 September 19 (43)Epub 09/19/2010.

Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth.

Kapetanovic S, Leister E, Nichols S, Miller T, Tassiopoulos K, Hazra R, Gelbard HA, Malee KM, Kammerer B, Mendez AJ, Williams PL,

AIDS.. 2010 June 1924 (10):1481-91. Epub 1900 01 01.

Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, Dewhurst S, Poluektova L, Gelbard HA, Gendelman HE

The Journal of immunology : official journal of the American Association of Immunologists.. 2010 January 15184 (2):746-56. Epub 12/04/2009.

Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008.

Joseph J, Clifford D, Douglas SD, Fox H, Gendelman HE, Gonzalez-Scarano F, Grant I, Major E, McArthur J,

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2009 September 4 (3):283-97. Epub 05/20/2009.

Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.

Eggert D, Dash PK, Serradji N, Dong CZ, Clayette P, Heymans F, Dou H, Gorantla S, Gelbard HA, Poluektova L, Gendelman HE

Journal of neuroimmunology.. 2009 August 18213 (1-2):47-59. Epub 06/21/2009.

Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment.

Schifitto G, Zhong J, Gill D, Peterson DR, Gaugh MD, Zhu T, Tivarus M, Cruttenden K, Maggirwar SB, Gendelman HE, Dewhurst S, Gelbard HA

Journal of neurovirology.. 2009 April 15 (2):176-86. Epub 1900 01 01.

Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.

DiCenzo R, Peterson DR, Cruttenden K, Mariuz P, Rezk NL, Hochreiter J, Gelbard H, Schifitto G

Antimicrobial agents and chemotherapy.. 2008 September 52 (9):3035-9. Epub 06/23/2008.

HIV-1 Tat activates neuronal ryanodine receptors with rapid induction of the unfolded protein response and mitochondrial hyperpolarization.

Norman JP, Perry SW, Reynolds HM, Kiebala M, De Mesy Bentley KL, Trejo M, Volsky DJ, Maggirwar SB, Dewhurst S, Masliah E, Gelbard HA

PloS one.. 2008 3 (11):e3731. Epub 11/14/2008.

The phospholipid mediator platelet-activating factor mediates striatal synaptic facilitation.

Lu SM, Tong N, Gelbard HA

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2007 June 2 (2):194-201. Epub 02/27/2007.

Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia.

Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S, Maggirwar SB

The Journal of immunology : official journal of the American Association of Immunologists.. 2007 March 1178 (5):3226-36. Epub 1900 01 01.

Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS.

Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2007 March 2 (1):93-6. Epub 12/16/2006.

HIV-1 trans activator of transcription protein elicits mitochondrial hyperpolarization and respiratory deficit, with dysregulation of complex IV and nicotinamide adenine dinucleotide homeostasis in cortical neurons.

Norman JP, Perry SW, Kasischke KA, Volsky DJ, Gelbard HA

The Journal of immunology : official journal of the American Association of Immunologists.. 2007 January 15178 (2):869-76. Epub 1900 01 01.

Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation.

Sui Z, Fan S, Sniderhan L, Reisinger E, Litzburg A, Schifitto G, Gelbard HA, Dewhurst S, Maggirwar SB

The Journal of immunology : official journal of the American Association of Immunologists.. 2006 July 1177 (1):702-11. Epub 1900 01 01.

Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons.

Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, Kovács AD, Potash MJ, Dewhurst S, Gelbard HA, Maggirwar SB

The European journal of neuroscience.. 2006 May 23 (10):2623-34. Epub 1900 01 01.

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report.

Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H

Neurology.. 2006 March 2866 (6):919-21. Epub 03/01/2006.

Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease.

Bellizzi MJ, Lu SM, Gelbard HA

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology.. 2006 March 1 (1):20-31. Epub 1900 01 01.

Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor.

Bellizzi MJ, Lu SM, Masliah E, Gelbard HA

The Journal of clinical investigation.. 2005 November 115 (11):3185-92. Epub 1900 01 01.

Adjunctive therapies for HIV-1 associated neurologic disease.

Perry SW, Norman JP, Gelbard HA

Neurotoxicity research.. 2005 October 8 (1-2):161-6. Epub 1900 01 01.

Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis.

Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2005 September 1425 (37):8375-85. Epub 1900 01 01.

Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis.

Nelson JA, Dou H, Ellison B, Uberti M, Xiong H, Anderson E, Mellon M, Gelbard HA, Boska M, Gendelman HE

Journal of neuroscience research.. 2005 May 1580 (4):562-75. Epub 1900 01 01.

HIV-1 transactivator of transcription protein induces mitochondrial hyperpolarization and synaptic stress leading to apoptosis.

Perry SW, Norman JP, Litzburg A, Zhang D, Dewhurst S, Gelbard HA

The Journal of immunology : official journal of the American Association of Immunologists.. 2005 April 1174 (7):4333-44. Epub 1900 01 01.

Productive infection of primary murine astrocytes, lymphocytes, and macrophages by human immunodeficiency virus type 1 in culture.

Nitkiewicz J, Chao W, Bentsman G, Li J, Kim SY, Choi SY, Grunig G, Gelbard H, Potash MJ, Volsky DJ

Journal of neurovirology.. 2004 December 10 (6):400-8. Epub 1900 01 01.

Antioxidants are required during the early critical period, but not later, for neuronal survival.

Perry SW, Norman JP, Litzburg A, Gelbard HA

Journal of neuroscience research.. 2004 November 1578 (4):485-92. Epub 1900 01 01.

Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.

DiCenzo R, Peterson D, Cruttenden K, Morse G, Riggs G, Gelbard H, Schifitto G

Antimicrobial agents and chemotherapy.. 2004 November 48 (11):4328-31. Epub 1900 01 01.

Activation of adenosine A2A receptor protects sympathetic neurons against nerve growth factor withdrawal.

Ramirez SH, Fan S, Maguire CA, Perry S, Hardiek K, Ramkumar V, Gelbard HA, Dewhurst S, Maggirwar SB

Journal of neuroscience research.. 2004 July 1577 (2):258-69. Epub 1900 01 01.

Immunohistochemical assessment of fractalkine, inflammatory cells, and human herpesvirus 7 in human salivary glands.

Latchney LR, Fallon MA, Culp DJ, Gelbard HA, Dewhurst S

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.. 2004 May 52 (5):671-81. Epub 1900 01 01.

Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3.

Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, Griffin JH, Zlokovic BV

Neuron.. 2004 February 1941 (4):563-72. Epub 1900 01 01.

Synapses and Sisyphus: life without paraplegin.

Gelbard HA

The Journal of clinical investigation.. 2004 January 113 (2):185-7. Epub 1900 01 01.

Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis.

Wang Z, Trillo-Pazos G, Kim SY, Canki M, Morgello S, Sharer LR, Gelbard HA, Su ZZ, Kang DC, Brooks AI, Fisher PB, Volsky DJ

Journal of neurovirology.. 2004 10 Suppl 1 :25-32. Epub 1900 01 01.

Neuroprotective strategies for HIV-1 associated dementia.

Dou H, Kingsley JD, Mosley RL, Gelbard HA, Gendelman HE

Neurotoxicity research.. 2004 6 (7-8):503-21. Epub 1900 01 01.

Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis.

Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE

The Journal of neuroscience : the official journal of the Society for Neuroscience.. 2003 October 823 (27):9162-70. Epub 1900 01 01.

Reduced expression of glutamate transporter EAAT2 and impaired glutamate transport in human primary astrocytes exposed to HIV-1 or gp120.

Wang Z, Pekarskaya O, Bencheikh M, Chao W, Gelbard HA, Ghorpade A, Rothstein JD, Volsky DJ

Virology.. 2003 July 20312 (1):60-73. Epub 1900 01 01.

Tumor necrosis factor-alpha in normal and diseased brain: Conflicting effects via intraneuronal receptor crosstalk?

Perry SW, Dewhurst S, Bellizzi MJ, Gelbard HA

Journal of neurovirology.. 2002 December 8 (6):611-24. Epub 1900 01 01.

HIV-1-associated dementia: a basic science and clinical perspective.

Diesing TS, Swindells S, Gelbard H, Gendelman HE

The AIDS reader. 2002 August 12 (8):358-68. Epub 1900 01 01.

Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism.

Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S, Maggirwar SB

Journal of neurochemistry.. 2001 August 78 (4):874-89. Epub 1900 01 01.

Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons.

Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, Gelbard HA

The European journal of neuroscience.. 2001 May 13 (10):1913-22. Epub 1900 01 01.

Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes.

Zhu Y, Gelbard HA, Roshal M, Pursell S, Jamieson BD, Planelles V

Journal of virology.. 2001 April 75 (8):3791-801. Epub 1900 01 01.

Release of the neuronal glycoprotein ICAM-5 in serum after hypoxic-ischemic injury.

Guo H, Tong N, Turner T, Epstein LG, McDermott MP, Kilgannon P, Gelbard HA

Annals of neurology.. 2000 October 48 (4):590-602. Epub 1900 01 01.

Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system.

Tong N, Perry SW, Zhang Q, James HJ, Guo H, Brooks A, Bal H, Kinnear SA, Fine S, Epstein LG, Dairaghi D, Schall TJ, Gendelman HE, Dewhurst S, Sharer LR, Gelbard HA

The Journal of immunology : official journal of the American Association of Immunologists.. 2000 February 1164 (3):1333-9. Epub 1900 01 01.

Functional interplay between nuclear factor-kappaB and c-Jun integrated by coactivator p300 determines the survival of nerve growth factor-dependent PC12 cells.

Maggirwar SB, Ramirez S, Tong N, Gelbard HA, Dewhurst S

Journal of neurochemistry.. 2000 February 74 (2):527-39. Epub 1900 01 01.

Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis.

James HJ, Sharer LR, Zhang Q, Wang HG, Epstein LG, Reed JC, Gelbard HA

Neuropathology and applied neurobiology.. 1999 October 25 (5):380-6. Epub 1900 01 01.

Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia.

Zheng J, Thylin MR, Ghorpade A, Xiong H, Persidsky Y, Cotter R, Niemann D, Che M, Zeng YC, Gelbard HA, Shepard RB, Swartz JM, Gendelman HE

Journal of neuroimmunology.. 1999 August 398 (2):185-200. Epub 1900 01 01.

HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity.

Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S

Journal of neurochemistry.. 1999 August 73 (2):578-86. Epub 1900 01 01.

Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium.

Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG

Neurology.. 1999 July 2253 (2):391-6. Epub 1900 01 01.

HIV-1-induced neuronal injury in the developing brain.

Epstein LG, Gelbard HA

Journal of leukocyte biology.. 1999 April 65 (4):453-7. Epub 1900 01 01.

Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss.

Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ

Brain research.. 1999 March 27823 (1-2):1-10. Epub 1900 01 01.

Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia.

Fine SM, Maggirwar SB, Elliott PR, Epstein LG, Gelbard HA, Dewhurst S

Journal of neuroimmunology.. 1999 March 195 (1-2):55-64. Epub 1900 01 01.

Neuroprotective strategies for HIV-1-associated neurologic disease.

Gelbard HA

Annals of the New York Academy of Sciences.. 1999 890 :312-3. Epub 1900 01 01.

Induction of fas ligand expression by an acutely lethal simian immunodeficiency virus, SIVsmmPBj14.

Hodge S, Novembre FJ, Whetter L, Gelbard HA, Dewhurst S

Virology.. 1998 December 20252 (2):354-63. Epub 1900 01 01.

Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption.

Deng SX, Panahian N, James H, Gelbard HA, Federoff HJ, Dewhurst S, Epstein LG

Journal of neuroscience methods.. 1998 September 183 (2):159-64. Epub 1900 01 01.

Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis.

Perry SW, Hamilton JA, Tjoelker LW, Dbaibo G, Dzenko KA, Epstein LG, Hannun Y, Whittaker JS, Dewhurst S, Gelbard HA

The Journal of biological chemistry.. 1998 July 10273 (28):17660-4. Epub 1900 01 01.

HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaB-independent mechanism.

New DR, Maggirwar SB, Epstein LG, Dewhurst S, Gelbard HA

The Journal of biological chemistry.. 1998 July 10273 (28):17852-8. Epub 1900 01 01.

Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.

Teicher MH, Andersen SL, Campbell A, Gelbard HA, Baldessarini RJ

Neuroscience letters.. 1998 May 15247 (2-3):99-102. Epub 1900 01 01.

In situ trypan blue staining of monolayer cell cultures for permanent fixation and mounting.

Perry SW, Epstein LG, Gelbard HA

BioTechniques.. 1997 June 22 (6):1020-1, 1024. Epub 1900 01 01.

Simultaneous in situ detection of apoptosis and necrosis in monolayer cultures by TUNEL and trypan blue staining.

Perry SW, Epstein LG, Gelbard HA

BioTechniques.. 1997 June 22 (6):1102-6. Epub 1900 01 01.

Expression of pro- and anti-apoptosis gene products in brains from paediatric patients with HIV-1 encephalitis.

Krajewski S, James HJ, Ross J, Blumberg BM, Epstein LG, Gendelman HE, Gummuluru S, Dewhurst S, Sharer LR, Reed JC, Gelbard HA

Neuropathology and applied neurobiology.. 1997 June 23 (3):242-53. Epub 1900 01 01.

Human immunodeficiency virus type 1 Tat protein induces death by apoptosis in primary human neuron cultures.

New DR, Ma M, Epstein LG, Nath A, Gelbard HA

Journal of neurovirology.. 1997 April 3 (2):168-73. Epub 1900 01 01.

Apoptosis in development and disease of the nervous system: II. Apoptosis in childhood neurologic disease.

Gelbard HA, Boustany RM, Schor NF

Pediatric neurology.. 1997 February 16 (2):93-7. Epub 1900 01 01.

Isolation and long-term culture of primary ocular human immunodeficiency virus type 1 isolates in primary astrocytes.

Canki M, Potash MJ, Bentsman G, Chao W, Flynn T, Heinemann M, Gelbard H, Volsky DJ

Journal of neurovirology.. 1997 February 3 (1):10-5. Epub 1900 01 01.

Human immunodeficiency virus encephalitis in SCID mice.

Persidsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet HS, Epstein L, Gelbard H, Flanagan E, Reinhard J, Pirruccello SJ, Gendelman HE

The American journal of pathology.. 1996 September 149 (3):1027-53. Epub 1900 01 01.

Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia.

Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, Gelbard HA

The Journal of biological chemistry.. 1996 June 28271 (26):15303-6. Epub 1900 01 01.

In situ amplification and detection of HIV-1 DNA in fixed pediatric AIDS brain tissue.

Sharer LR, Saito Y, Da Cunha A, Ung PC, Gelbard HA, Epstein LG, Blumberg BM

Human pathology.. 1996 June 27 (6):614-7. Epub 1900 01 01.

The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes.

Nottet HS, Flanagan EM, Flanagan CR, Gelbard HA, Gendelman HE, Reinhard JF

Journal of neurovirology.. 1996 April 2 (2):111-7. Epub 1900 01 01.

Neuropathogenesis of AIDS.

Dewhurst S, Gelbard HA, Fine SM

Molecular medicine today. 1996 January 2 (1):16-23. Epub 1900 01 01.

Activation of nuclear factor kappa B in brains from children with HIV-1 encephalitis.

Dollard SC, James HJ, Sharer LR, Epstein LG, Gelbard HA, Dewhurst S

Neuropathology and applied neurobiology.. 1995 December 21 (6):518-28. Epub 1900 01 01.

HIV-1 encephalopathy in children.

Gelbard HA, Epstein LG

Current opinion in pediatrics.. 1995 December 7 (6):655-62. Epub 1900 01 01.

Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy.

Gelbard HA, James HJ, Sharer LR, Perry SW, Saito Y, Kazee AM, Blumberg BM, Epstein LG

Neuropathology and applied neurobiology.. 1995 June 21 (3):208-17. Epub 1900 01 01.

Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA.

Talley AK, Dewhurst S, Perry SW, Dollard SC, Gummuluru S, Fine SM, New D, Epstein LG, Gendelman HE, Gelbard HA

Molecular and cellular biology.. 1995 May 15 (5):2359-66. Epub 1900 01 01.

Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin.

Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang D

Journal of virology.. 1994 July 68 (7):4628-35. Epub 1900 01 01.

HIV-1 infection of the developing nervous system: central role of astrocytes in pathogenesis.

Blumberg BM, Gelbard HA, Epstein LG

Virus research.. 1994 May 32 (2):253-67. Epub 1900 01 01.

Persistent increases in dopamine D2 receptor mRNA expression in basal ganglia following kindling.

Gelbard HA, Applegate CD

Epilepsy research.. 1994 January 17 (1):23-9. Epub 1900 01 01.

Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol.

Teicher MH, Barber NI, Gelbard HA, Gallitano AL, Campbell A, Marsh E, Baldessarini RJ

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.. 1993 September 9 (2):147-56. Epub 1900 01 01.

Seasonal mood disorders. Patterns of seasonal recurrence in mania and depression.

Faedda GL, Tondo L, Teicher MH, Baldessarini RJ, Gelbard HA, Floris GF

Archives of general psychiatry.. 1993 January 50 (1):17-23. Epub 1900 01 01.

Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: implications for AIDS neuropathogenesis.

Gelbard HA, Dzenko KA, DiLoreto D, del Cerro C, del Cerro M, Epstein LG

Developmental neuroscience.. 1993 15 (6):417-22. Epub 1900 01 01.

Increased prevalence of electrophysiological abnormalities in children with psychological, physical, and sexual abuse.

Ito Y, Teicher MH, Glod CA, Harper D, Magnus E, Gelbard HA

The Journal of neuropsychiatry and clinical neurosciences.. 1993 5 (4):401-8. Epub 1900 01 01.

Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease.

Mizrachi Y, Genis P, Volsky DJ, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, Resnick L, Mizrachi Y, Volsky DJ

The Journal of experimental medicine.. 1992 December 1176 (6):1703-18. Epub 1900 01 01.

Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications.

Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT

Archives of neurology.. 1991 December 48 (12):1281-4. Epub 1900 01 01.

Dopamine D1 autoreceptor function: possible expression in developing rat prefrontal cortex and striatum.

Teicher MH, Gallitano AL, Gelbard HA, Evans HK, Marsh ER, Booth RG, Baldessarini RJ

Brain research. Developmental brain research.. 1991 November 1963 (1-2):229-35. Epub 1900 01 01.

Neonatal depletion of dopamine decreases D1 and forskolin binding sites in rat striatum

Gelbard, H.A.; Teicher, M.H.; Beers, N.B.; Gallitano, A. and R.J. Baldessarini.

Posters in Neuroscience. 1991; 1: 9-11.

Dopamine D1 receptor development depends on endogenous dopamine.

Gelbard HA, Teicher MH, Baldessarini RJ, Gallitano A, Marsh ER, Zorc J, Faedda G

Brain research. Developmental brain research.. 1990 October 156 (1):137-40. Epub 1900 01 01.

Postnatal development of dopamine D1 and D2 receptor sites in rat striatum.

Gelbard HA, Teicher MH, Faedda G, Baldessarini RJ

Brain research. Developmental brain research.. 1989 September 149 (1):123-30. Epub 1900 01 01.

Characteristics of [3H]1 alpha, 25-(OH)2D3 binding to nuclear fractions from rat pituitary adenoma GH3 cells.

Gelbard HA, Stern PH, U'Prichard DC

Life sciences.. 1981 September 729 (10):1051-6. Epub 1900 01 01.

1 alpha, 25-Dihydroxyvitamin D3 nuclear receptors in pituitary.

Gelbard HA, Stern PH, U'Prichard DC

Science.. 1980 September 12209 (4462):1247-9. Epub 1900 01 01.

Books

Encyclopedia of AIDS (2015)

Chapter: HAND adjunctive therapies: reversing neuronal injury

Authors: Marker DF, Fitzgerald, T and Gelbard HA

Publisher: Springer Science + Business Media, New York 2015

Microglia in Health and Disease (2014)

Chapter: Human immunodeficiency virus

Authors: Marker DF, Lu S-M and Gelbard HA

Publisher: Science + Business Media, New York 2014

The Neurology of AIDS (2012)

Chapter: Development of Adjunctive Therapies for the Neurological Manifestations of AIDS: HAND and Painful Neuropathy

Authors: Gelbard, H.A. and Lipton, S.A.

Publisher: Oxford Press, New York 2012

The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment. (2008)

Chapter: Neuroimmunology and the Pathogenesis of HIV-1 Encephalitis in the HAART Era: Implications for Neuroprotective Treatment.

Authors: Perry, S.W. and Gelbard, H.A.

Publisher: ASM Press, New York 2008

Encyclopedia of Neuroscience (2008)

Chapter: Infectious agents in neurodegenerative disease

Authors: Bellizzi, M.J and Gelbard, H.A.

Publisher: Academic Press, Oxford 2008

The Neurology of AIDS - 2nd Edition (2004)

Chapter: Development of Adjunctive Therapies for the Neurological Manifestations of AIDS: Dementia and Painful Neuropathy

Authors: Lipton, S.A. and Gelbard, H.A.

Publisher: Chapman and Hall, New York 2004

AIDS and Other Manifestations of HIV Infections - 4th edition (2002)

Chapter: The Neuropathogenesis of HIV-1 Infection

Authors: Gendelman, H.E., Diesing, S., Gelbard, H.A., and S.Swindells

Publisher: In Wormser (ed.) 2002

Apoptosis in Neurobiology (1999)

Chapter: HIV-1 and Apoptosis in the Nervous System

Authors: Gelbard, H.A.

Publisher: CRC Methods of Neurobiology, CRC Press, Boca Raton 1999

Academy of Science (1999)

Chapter: Neuroprotective strategies for HIV-1 associated neurologic disease

Authors: Gelbard, H.A.

Publisher: Ann., New York 1999

The Neurology of AIDS (1998)

Chapter: HIV-induced neurotoxicity in the developing central nervous system

Authors: Gelbard, H.A.

Publisher: Chapman and Hall, New York, New York 1998

Cell Death and Diseases of the Nervous System (1998)

Chapter: Infection of the CNS: Evidence for Apoptosis of Neural Cells

Authors: Gelbard, H.A.

Publisher: Humana Press, New Jersey 1998

Textbook of Neuropsychiatry - Third Edition (1997)

Chapter: Neuropsychiatric disorders of childhood and adolescence

Authors: Teicher, M.H., Anderson, S.L., Glod, C.A., Navalta, C.P., and Gelbard, H.A.

Publisher: In Yudofsky and Hales (eds.) 1997

Severe Stress and Mental Disturbances in Children (1996)

Chapter: Neurophysiological mechanisms of stress response in children

Authors: Teicher, M.H., Ito, Y., Glod, C.A., Schiffer, F., and Gelbard, H.A.

Publisher: In Pheffer (ed.) 1996

Technical Advances in AIDS Research in the Human Nervous System (1995)

Chapter: HIV-1-derived neurotoxic factors: effects on human neuronal cultures

Authors: Gelbard, H.A., Dzenko, K.A., Wang, L., Talley, A., James, H., and L. Epstein

Publisher: Plenum Press, New York 1995

Biological and Neurobehavioral Studies in Borderline Personality (1994)

Chapter: Early Abuse, Limbic System Dysfunction, and Borderline Personality Disorder

Authors: Teicher, M.H., Ito, Y., Glod, C.A., Schiffer, F., and Gelbard, H.A.

Publisher: American Psychiatric Press, Inc. 1994

New Concepts in AIDS Pathogenesis (1994)

Chapter: Experimental model systems for studies of HIV-associated CNS disease

Authors: Gendelman, H.E., Genis, P., Jett, M., Bernton, E.W., Gelbard, H.A., Cvetkovich, T.A., Lazar, E.S., del Cerro, M., and Epstein, L.G.

Publisher: Marcel Dekker 1994

Psychiatry: A World Perspective Volume (1990)

Chapter: Development of dopamine D receptor system depends on endogenous dopamine

Authors: Gelbard, H.A., Teicher, M.H., Baldessarini, R.J., Gallitano, A., Marsh, E.R., Zorc, J. and Faedda, G.

Publisher: Elsevier Science Publishers, Amsterdam 1990

Steroid Hormone Regulations of the Brain (1981)

Chapter: I alpha, 25-(OH) vitamin D receptors in the pituitary: Characterization and relation to dopaminergic mechanisms

Authors: Gelbard, H.A., Stern, P.J. & U'Prichard, D.C.

Publisher: Pergamon Press, Oxford, England 1981